Cerebral Amyloid Angiopathy: How Does It Raise Stroke

What Is Cerebral Amyloid Angiopathy and Why Does It Matter?

An October 1 report from Harvard Health Publishing highlights a condition that connects two major concerns in brain health: declining cognitive function and stroke caused by bleeding. Cerebral amyloid angiopathy, commonly shortened to CAA, affects small vessels near the brain's surface. Deposits of amyloid protein can make these vessels vulnerable to leakage or rupture, potentially producing anything from tiny bleeds to a disabling hemorrhagic stroke. The report provides a timely explanation of an established disease. [Harvard Health report](https://www.health.harvard.edu/heart-health/cerebral-amyloid-angiopathy-a-little-known-cause-of-cognitive-decline-and-stroke)

CAA can also contribute to changes in thinking and memory. The National Institute of Neurological Disorders and Stroke includes it among vascular conditions associated with cognitive impairment and notes that MRI may reveal multiple small brain bleeds. This matters because an assessment of cognitive decline may need to consider damage to blood vessels alongside other possible causes. Memory symptoms alone cannot identify which process is responsible. [NINDS overview of dementias](https://www.ninds.nih.gov/health-information/disorders/dementias)

How Do Doctors Diagnose Cerebral Amyloid Angiopathy?

A major diagnostic advance came with the Boston criteria version 2.0, published in The Lancet Neurology in 2022. Researchers evaluated 341 participants from 10 medical centers, all aged 50 or older, using MRI and brain tissue findings. The criteria incorporate patterns of bleeding and selected changes in the brain's white matter to support a diagnosis of probable CAA without routinely requiring a brain biopsy. The study's age threshold is an eligibility criterion, not a claim that the disease always begins at 50. [Boston criteria diagnostic study](https://pmc.ncbi.nlm.nih.gov/articles/PMC9389452/)

These criteria have practical limits. A separate 2024 study in Neurology examined 54 participants from community and memory clinic settings and found low diagnostic accuracy among people without symptomatic brain hemorrhage. That finding cautions against treating MRI criteria as a universal screening test for anyone with forgetfulness. A neurologist must interpret the scan in context, consider alternative explanations and recognize that a probable diagnosis still carries uncertainty. [MRI and neuropathology validation study](https://www.neurology.org/doi/10.1212/WNL.0000000000209386)

How Can Treatment Reduce Risk After a CAA Diagnosis?

A diagnosis can change everyday treatment decisions. A clinical management review emphasizes blood pressure control and individualized assessment of antiplatelet medicines, such as aspirin, and anticoagulants used for conditions including atrial fibrillation. These medicines may prevent dangerous clots but can also increase bleeding risk. Their benefits and harms depend on the reason for treatment, previous bleeding and MRI findings. Patients should arrange a medication review with their clinicians rather than independently stopping a prescribed medicine. [Clinical management review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9097498/)

Families also need a clear emergency plan. Sudden facial drooping, weakness on one side, speech difficulty, loss of vision or balance, or an unexplained severe headache require immediate emergency assessment. Symptoms cannot reliably distinguish a blocked artery from a brain bleed, and symptoms that disappear still need urgent evaluation. Call the local emergency number and note when the person was last known to be well. [American Stroke Association warning signs](https://www.stroke.org/en/help-and-support/resource-library/lets-talk-about-stroke/stroke-tia-and-warning-signs)